MX380799B - Ácidos propiónicos 3-sustituidos como inhibidores de la integrina alfa v. - Google Patents
Ácidos propiónicos 3-sustituidos como inhibidores de la integrina alfa v.Info
- Publication number
- MX380799B MX380799B MX2019005244A MX2019005244A MX380799B MX 380799 B MX380799 B MX 380799B MX 2019005244 A MX2019005244 A MX 2019005244A MX 2019005244 A MX2019005244 A MX 2019005244A MX 380799 B MX380799 B MX 380799B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- integrin
- inhibitors
- alpha
- propionic acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662418848P | 2016-11-08 | 2016-11-08 | |
| PCT/US2017/060376 WO2018089353A1 (en) | 2016-11-08 | 2017-11-07 | 3-substituted propionic acids as alpha v integrin inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019005244A MX2019005244A (es) | 2019-08-05 |
| MX380799B true MX380799B (es) | 2025-03-12 |
Family
ID=60409432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019005244A MX380799B (es) | 2016-11-08 | 2017-11-07 | Ácidos propiónicos 3-sustituidos como inhibidores de la integrina alfa v. |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US10968219B2 (enExample) |
| EP (1) | EP3538525B1 (enExample) |
| JP (1) | JP7097358B2 (enExample) |
| KR (1) | KR102505629B1 (enExample) |
| CN (1) | CN110167935B (enExample) |
| AR (1) | AR110153A1 (enExample) |
| AU (1) | AU2017359023B2 (enExample) |
| CA (1) | CA3042707A1 (enExample) |
| CL (1) | CL2019001264A1 (enExample) |
| CO (1) | CO2019005824A2 (enExample) |
| DK (1) | DK3538525T3 (enExample) |
| EA (1) | EA038164B1 (enExample) |
| ES (1) | ES2925173T3 (enExample) |
| HR (1) | HRP20220990T1 (enExample) |
| HU (1) | HUE059708T2 (enExample) |
| IL (1) | IL266473B (enExample) |
| LT (1) | LT3538525T (enExample) |
| MA (1) | MA46743A (enExample) |
| MX (1) | MX380799B (enExample) |
| MY (1) | MY199931A (enExample) |
| NZ (1) | NZ754207A (enExample) |
| PE (1) | PE20191647A1 (enExample) |
| PL (1) | PL3538525T3 (enExample) |
| PT (1) | PT3538525T (enExample) |
| RS (1) | RS63483B1 (enExample) |
| SI (1) | SI3538525T1 (enExample) |
| SM (1) | SMT202200338T1 (enExample) |
| TW (1) | TWI763733B (enExample) |
| WO (1) | WO2018089353A1 (enExample) |
| ZA (1) | ZA201903665B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| US10851098B2 (en) * | 2016-11-08 | 2020-12-01 | Bristol-Myers Squibb Company | Azole amides and amines as alpha v integrin inhibitors |
| CA3042707A1 (en) * | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | 3-substituted propionic acids as .alpha.v integrin inhibitors |
| WO2018089355A1 (en) * | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors |
| BR112019012515A2 (pt) | 2016-12-29 | 2019-11-19 | Saint Louis University | antagonistas de integrina |
| AU2018227417B2 (en) | 2017-02-28 | 2021-12-23 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| TW201835078A (zh) | 2017-02-28 | 2018-10-01 | 美商萊築理公司 | αvβ6整合蛋白之抑制劑 |
| EP4086254B1 (en) | 2018-08-29 | 2024-12-18 | Morphic Therapeutic, Inc. | Integrin inhibitors |
| CN112969687B (zh) | 2018-10-30 | 2024-08-23 | 吉利德科学公司 | 作为α4β7整合素抑制剂的喹啉衍生物 |
| ES3003232T3 (en) | 2018-10-30 | 2025-03-10 | Gilead Sciences Inc | Compounds for inhibition of alpha4beta7 integrin |
| ES2987796T3 (es) | 2018-10-30 | 2024-11-18 | Gilead Sciences Inc | Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias |
| CA3114240C (en) | 2018-10-30 | 2023-09-05 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| CN109824495B (zh) * | 2019-02-02 | 2022-12-09 | 盐城师范学院 | 一种新型偶联反应在制备碳-碳键结构化合物中的应用 |
| CN114222730B (zh) | 2019-08-14 | 2024-09-10 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
| GB202010626D0 (en) | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
| WO2025064802A1 (en) * | 2023-09-21 | 2025-03-27 | Morphic Therapeutic, Inc. | INHIBITING HUMAN INTEGRIN α5β1 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0451790A1 (de) * | 1990-04-12 | 1991-10-16 | Hoechst Aktiengesellschaft | 3,5-disubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung |
| US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| ZA972195B (en) | 1996-03-15 | 1998-09-14 | Du Pont Merck Pharma | Spirocycle integrin inhibitors |
| JP2001524481A (ja) | 1997-11-26 | 2001-12-04 | デュポン ファーマシューティカルズ カンパニー | αＶβ３アンタゴニストとしての１，３，４−チアジアゾール類および１，３，４−オキサジアゾール類 |
| WO1999030709A1 (en) * | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| WO2000009503A1 (en) * | 1998-08-13 | 2000-02-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| JP4615826B2 (ja) | 2001-01-29 | 2011-01-19 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 置換インドールおよびインテグリンアンタゴニストとしてのそれらの使用 |
| US20050004200A1 (en) * | 2002-12-20 | 2005-01-06 | Pharmacia Corporation | Pyrazole compounds as integrin receptor antagonists derivatives |
| JP2006518333A (ja) * | 2002-12-20 | 2006-08-10 | ファルマシア・コーポレーション | インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸 |
| WO2006108040A1 (en) | 2005-04-05 | 2006-10-12 | Janssen Pharmaceutica, N.V. | Substituted indoles and their use as integrin antagonists |
| TW200800999A (en) * | 2005-09-06 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| AR059224A1 (es) | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
| WO2007141473A1 (en) | 2006-06-09 | 2007-12-13 | Astrazeneca Ab | N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl] -l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors |
| WO2008125811A1 (en) * | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
| WO2011026937A1 (en) | 2009-09-04 | 2011-03-10 | Basf Se | Process for preparing 1-phenylpyrazoles |
| JP2013509442A (ja) | 2009-10-29 | 2013-03-14 | サートリス ファーマシューティカルズ， インコーポレイテッド | サーチュイン調節因子としての二環式ピリジンおよび類似体 |
| ITFI20100019A1 (it) | 2010-02-12 | 2011-08-13 | Univ Firenze | Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori. |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EP3259271B1 (en) | 2015-02-19 | 2021-05-05 | SciFluor Life Sciences, Inc. | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |
| CA2981371A1 (en) * | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| CA3042707A1 (en) * | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | 3-substituted propionic acids as .alpha.v integrin inhibitors |
-
2017
- 2017-11-07 CA CA3042707A patent/CA3042707A1/en active Pending
- 2017-11-07 KR KR1020197016082A patent/KR102505629B1/ko active Active
- 2017-11-07 US US16/347,844 patent/US10968219B2/en active Active
- 2017-11-07 CN CN201780082473.2A patent/CN110167935B/zh active Active
- 2017-11-07 PE PE2019000940A patent/PE20191647A1/es unknown
- 2017-11-07 SI SI201731195T patent/SI3538525T1/sl unknown
- 2017-11-07 ES ES17801230T patent/ES2925173T3/es active Active
- 2017-11-07 PL PL17801230.8T patent/PL3538525T3/pl unknown
- 2017-11-07 MY MYPI2019002576A patent/MY199931A/en unknown
- 2017-11-07 RS RS20220759A patent/RS63483B1/sr unknown
- 2017-11-07 HR HRP20220990TT patent/HRP20220990T1/hr unknown
- 2017-11-07 SM SM20220338T patent/SMT202200338T1/it unknown
- 2017-11-07 MA MA046743A patent/MA46743A/fr unknown
- 2017-11-07 WO PCT/US2017/060376 patent/WO2018089353A1/en not_active Ceased
- 2017-11-07 MX MX2019005244A patent/MX380799B/es unknown
- 2017-11-07 EA EA201991122A patent/EA038164B1/ru unknown
- 2017-11-07 LT LTEPPCT/US2017/060376T patent/LT3538525T/lt unknown
- 2017-11-07 DK DK17801230.8T patent/DK3538525T3/da active
- 2017-11-07 EP EP17801230.8A patent/EP3538525B1/en active Active
- 2017-11-07 NZ NZ754207A patent/NZ754207A/en unknown
- 2017-11-07 JP JP2019523576A patent/JP7097358B2/ja active Active
- 2017-11-07 PT PT178012308T patent/PT3538525T/pt unknown
- 2017-11-07 AU AU2017359023A patent/AU2017359023B2/en active Active
- 2017-11-07 HU HUE17801230A patent/HUE059708T2/hu unknown
- 2017-11-08 TW TW106138533A patent/TWI763733B/zh active
- 2017-11-08 AR ARP170103105A patent/AR110153A1/es unknown
-
2019
- 2019-05-06 IL IL266473A patent/IL266473B/en unknown
- 2019-05-08 CL CL2019001264A patent/CL2019001264A1/es unknown
- 2019-06-04 CO CONC2019/0005824A patent/CO2019005824A2/es unknown
- 2019-06-07 ZA ZA2019/03665A patent/ZA201903665B/en unknown
-
2021
- 2021-02-24 US US17/184,179 patent/US11884661B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX380799B (es) | Ácidos propiónicos 3-sustituidos como inhibidores de la integrina alfa v. | |
| MX2019005306A (es) | Compuestos mono y espirociclicos que continen ciclobutano y azetidina como inhibidores de la integrina alfa v. | |
| MX2019005233A (es) | Pirrolamidas como inhibidores de la integrina alfa v. | |
| MX2019005243A (es) | Derivados de indazol como antagonistas de integrina alfa v. | |
| CO2020005459A2 (es) | Compuestos bicíclicos en puente como moduladores del receptor farnesoide x | |
| UY36244A (es) | Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen | |
| EA201892710A1 (ru) | Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| UY34960A (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| UY34959A (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| UY35971A (es) | Macrociclos con grupos p2? aromáticos como inhibidores del factor xia | |
| UY35972A (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| MX2016009013A (es) | Derivados de heterociclilo biciclicos como inhibores de cinasa-4 asociada al receptor de interleucina-1 (irak4). | |
| ECSP17026210A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| MX2017012558A (es) | Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para su uso. | |
| CO7131358A2 (es) | Compuestos de n-alquiltriazol como antagonistas de lpar | |
| MX2019005234A (es) | Amidas y aminas de azol como inhibidores de integrina alfa v. | |
| CO2020005486A2 (es) | Compuestos espirocíclicos como moduladores del receptor farnesoide x | |
| CO7160077A2 (es) | Compuestos de pirazol sustituidos como antagonistas de lpar | |
| CO2017003305A2 (es) | Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa | |
| CU20160195A7 (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| ECSP13012495A (es) | Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina | |
| CL2019003564A1 (es) | Compuestos y composiciones para inducir la condrogénesis. |